Intelligent Bio Solutions (INBS) Long-Term Deferred Tax (2021 - 2023)
Intelligent Bio Solutions' quarterly Long-Term Deferred Tax came in at $7.6 million in Q1 2023, up 1.17% year-on-year from $7.5 million in Q1 2022, and down 6.79% quarter-over-quarter from $8.1 million in Q4 2022.
Intelligent Bio Solutions has reported Long-Term Deferred Tax for 3 years, with the latest figure at $7.6 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Intelligent Bio Solutions | 13.61 Mn | 12.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 7.60 Mn |
| Dec 31, 2022 | 8.15 Mn |
| Sep 30, 2022 | 6.33 Mn |
| Mar 31, 2022 | 7.51 Mn |
| Dec 31, 2021 | 6.46 Mn |
| Sep 30, 2021 | 7.22 Mn |